Cue Biopharma Announces Pricing of Approximately $20 Million Public Offering

Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros…